Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Morphine sulphate tablets in hospice practice.

J D Bonifant1, M Clark-Reynolds

  • 1Mary Potter Hospice, Wellington, New Zealand.

Postgraduate Medical Journal
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Hallerman-Strieff syndrome. Case report.

The New Zealand medical journalยท1969
See all related articles

Sustained release morphine sulphate tablets (MST) are effective and well-tolerated for pain management in palliative and terminal care. This study confirms MST

Area of Science:

  • Palliative Care
  • Pain Management
  • Pharmacology

Background:

  • Sustained release morphine sulphate tablets (MST Continus) have been used in New Zealand since 1984.
  • MST has become a primary opioid for palliative and terminal care.
  • The Mary Potter Hospice, established in 1978, is New Zealand's largest hospice.

Purpose of the Study:

  • To document current hospice usage of MST.
  • To assess the efficacy and tolerability of MST in palliative care patients.
  • To identify reasons for MST cessation.

Main Methods:

  • Prospective collection of records for 100 consecutive patients prescribed MST.
  • Analysis of patient data within the Mary Potter Hospice Programme.
  • Documentation of MST dosage, reasons for use, and cessation.

Related Experiment Videos

Main Results:

  • MST was widely tolerated and highly successful in controlling pain for most patients.
  • Dosage requirements varied widely and were independent of pathology, age, or prior analgesic exposure.
  • Inappropriate MST use was readily identifiable.
  • Common reasons for stopping MST were patient death or moribund state, not nausea, vomiting, confusion, or altered consciousness.

Conclusions:

  • MST is a highly effective and well-tolerated opioid for pain management in palliative and terminal care.
  • Current hospice usage demonstrates the advantages of MST in this setting.
  • The study provides evidence supporting MST's role as a principal opioid in palliative and terminal care.